Skip to content

GHRP-6

Potent synthetic hexapeptide GH-releasing peptide. Also studied for appetite stimulation and anti-metabolic properties. GH release, appetite stimulation, muscle building, growth agonist.

Intelligence Profile

Clinical Applications

GHRP-6 (Growth Hormone-Releasing Peptide-6) is being investigated across several therapeutic areas, though clinical evidence remains limited to preclinical studies. The available research suggests potential applications in cardiovascular, neurological, pulmonary, and renal conditions.

Cardiovascular Applications

Recent preclinical research indicates GHRP-6 may have cardioprotective effects. A 2026 study demonstrated that GHRP-6 ameliorated post-infarct ventricular remodeling and systolic dysfunction in a permanent coronary ligation model, suggesting potential utility in treating heart failure following myocardial infarction.

Neurological and Cognitive Applications

GHRP-6 shows promise in addressing cognitive decline. When co-administered with epidermal growth factor (EGF), GHRP-6 attenuated cognitive decline in preclinical models, with both behavioral and molecular evidence supporting neuroprotective effects. This suggests potential applications in neurodegenerative conditions, though human studies are needed.

Pulmonary Applications

Research indicates GHRP-6 may help treat acute lung injury and prevent its progression to interstitial fibrosis. A 2026 study found the peptide ameliorated acute lung injury and reduced subsequent fibrotic changes, pointing to potential therapeutic value in severe respiratory conditions.

Renal Applications

GHRP-6 has been investigated for acute kidney injury treatment. A hydrogel formulation designed for metabolic regulation showed therapeutic potential in preclinical models, suggesting applications in nephrology.

Performance Enhancement Context

A 2026 review noted GHRP-6 among performance-enhancing peptides that modulate the GH-IGF1 axis, highlighting a gap between limited clinical evidence and patient self-administration practices.

Clinical Evidence Limitations

Important limitation: No completed clinical trials were identified for GHRP-6. All evidence comes from preclinical studies, primarily in animal models. The therapeutic potential suggested by these studies requires validation through properly designed human clinical trials before any clinical recommendations can be made.

This information is for educational purposes only and should not be considered medical advice. Consult healthcare professionals for treatment decisions.

Free account required

Clinical data requires a free AXIFI account to access clinical data, safety profiles, and research papers.